Olympus completes transfer of its regenerative medicine business Olympus RMS to Rohto Pharmaceutical
March 23, 2021
Olympus Corporation (”Olympus” – Director, Representative Executive Officer, President and CEO: Yasuo Takeuchi) today announced the completion of the transfer of its subsidiary, Olympus RMS Corporation (“Olympus RMS”- President and Representative Director: Masahiko Hamano), which specializes in manufacturing and development of regenerative medicines, to Rohto Pharmaceutical Co., Ltd. (“Rohto”- President and Chief Operating Officer: Masashi Sugimoto).
Press releases are company announcements that are directed at the news media.
Information posted on this site is current and accurate only at the time of their original publication date, and may now be outdated or inaccurate.